Clinical Trial Update: A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and effect of the JAK2 inhibitor ruxolitinib in patients with multiple myeloma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2012-01-23